BTIG analyst Mark Massaro maintained a Buy rating on Exact Sciences (EXAS – Research Report) yesterday and set a price target of $85.00. The company’s shares closed yesterday at $57.51.
According to TipRanks, Massaro is an analyst with an average return of -15.3% and a 31.56% success rate. Massaro covers the Healthcare sector, focusing on stocks such as Exact Sciences, Guardant Health, and Adaptive Biotechnologies.
Exact Sciences has an analyst consensus of Strong Buy, with a price target consensus of $89.77, representing a 56.09% upside. In a report released yesterday, Piper Sandler also maintained a Buy rating on the stock with a $80.00 price target.
See the top stocks recommended by analysts >>
EXAS market cap is currently $10.44B and has a P/E ratio of -50.66.
Based on the recent corporate insider activity of 77 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EXAS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Exact Sciences (EXAS) Company Description:
Founded in 1995, Wisconsin-based Exact Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer.
Read More on EXAS:
- Exact Sciences price target lowered to $90 from $100 at Canaccord
- Exact Sciences price target lowered to $85 from $90 at BTIG
- Exact Sciences sees FY24 revenue $2.81B-$2.85B, consensus $2.83B
- Exact Sciences reports Q4 EPS (27c), consensus (46c)
- EXACT Sciences options imply 8.3% move in share price post-earnings
